ZYDUS LIFESCIENCES Q1 EARNINGS
Q4 results: Stable costs boost India Inc. profits
Steady costs and firm domestic demand supported corporate performance in the March quarter.
Eris Lifesciences Q4 Results: Net profit jumps over 29% to Rs 80 crore
The Ahmedabad-based drug maker reported a net profit of Rs 61.5 crore during the corresponding quarter of the previous year. Revenue of Q4FY 24 grew by 37% YoY to Rs 551 crore. The net debt on March 31 stood at Rs 2700 crore.
Zydus Lifesciences Q4 Results: Drug makers posts threefold YoY jump in net profit to Rs 1,182 crore
Zydus Lifesciences on Friday reported Rs 1,182 crore net profit in Q4FY24, a threefold year-on-year (YoY) jump led by growth in US, India, Europe and emerging market sales.
Zydus Q4 Results: Net profit surges 4-fold to Rs 1,182 crore; revenue at Rs 5,534 cr
Zydus Lifesciences on Friday said its consolidated net profit surged four-fold to Rs 1,182 crore for the fourth quarter ended March 31, 2024 on higher sales. The drug firm had reported a net profit of Rs 297 crore in the January-March quarter of the 2022-23 fiscal.
Apar Industries shares zoom 8% after company reports Q4 results, announces Rs 51 dividend
Apar Industries recorded a fresh 52-week high on Tuesday apparently propelled by its Q4 revenue growth of 9% YoY. Its PAT, however, declined 3% YoY. The stock has zoomed 208% in the last one year.
Zydus Wellness shares rally nearly 4% after reporting PAT at Rs 150 crore; declares Rs 5 dividend
Zydus Wellness shares surged 3.8% on BSE, reaching a new 52-week high at Rs 1,750.20 following a 4% YoY rise in Q4 FY24 profit after tax to Rs 150.3 crore. The board announced a dividend of Rs 5 per share, with the record date set for July 19.
- Go To Page 1
Q4 results this week: Zomato, Airtel, M&M among 501 companies set to announce earnings this week
Some notable companies that will announce their earnings this week include Varun Beverages, Zomato, Airtel, Siemens, Power Finance Corp, Mahindra and Mahindra, HAL, and JSW Steel, among others. Overall, around 501 companies are set to release their quarterly numbers this week.
Foram Parekh on what to bet on in pharma pack
Foram Parekh shares insights on CDMO companies' positive outlook post-Covid correction, potential impact of Biosecure Law, concerns about Laurus's earnings improvement, Sun Pharma's specialty sales focus, and recommendations for pharma sector growth with Lupin and Dr Reddy's.
Stocks to buy: Will pharma scrips keep rising? 3 stocks with potential upside of up to 30.6%
In the December 2023 quarter, the pharma stock universe (89 stocks) reported 12% and 27% y-o-y growth in revenue and PAT, respectively. Comparatively, the aggregate revenue and PAT of Nifty 500 companies (excluding pharma) grew by 5.3% and 20%, respectively. The sector fundamentals are stable, but stretched valuations could hinder price performance.
Zydus Lifesciences net profit jumps 27% in Q3FY24, announced buyback
Zydus Lifesciences on Tuesday reported Rs 789.6 crore net profit in Q3FY24, a year-on-year (YoY) jump of 27% led by growth in India, Europe and emerging market formulation sales.
Zydus Lifesciences Q3 Results: Firm beats profit estimates; approves shares buyback
Indian generic drugmaker Zydus Lifesciences reported a bigger-than-expected rise in third-quarter profit on Friday, driven by strong sales in its domestic and overseas markets.
Sectoral tailwinds and stronger balance sheets: 5 largecap stocks with right mix of two important ratios
There are some sectors where large players have an edge, because the nature of the business is such that there are phases where ability to stay in the game and cash on the balance sheet matter most. When the tide turns in favor of that sector, these large companies are able to make most of it. One sector which has gone through a phase of realignment of business and readjustment of valuations for many years and has once again come in limelight is the pharma space. Right from ability to deal with USFDA, not rely just on product segment to how to deal with uncertainty of supply chain which is dependent on China, Indian pharma companies have come a long way.
Wipro Q3 Results: Consolidated PAT drops 12% YoY to Rs 2,694 crore; Re 1/share interim dividend announced
Wipro Q3 Results: Wipro reported disappointing Q3 results, with a decline in net profit and revenue. The company's consolidated net profit decreased by nearly 12% YoY to Rs 2,694 crore, while the consolidated revenue dropped 4.4% to Rs 22,205 crore. The board recommended an interim dividend of Re 1 per share. For the nine months ended December, Wipro's consolidated revenue rose by only 0.4% to Rs 67,552 crore, while the net profit declined by nearly 1% to Rs 8,211 crore. Wipro expects revenue from its IT Services business to be in the range of $2.62 billion to $2.67 billion for the quarter ending March.
Good for all market conditions: 6 largecap stocks with right mix of RoE & RoCE
There is sunshine all around, better than expected GDP numbers, further decline in oil prices, falling US bond yields and clear indication from RBI that it is in no mood to increase interest rates any further. So while macros are bullish and could not get better, it is time to spend some time in understanding what stocks are you buying and why that stock at this point of time only. Also if one is thinking about increasing the exposure it would be better to stay with large caps as they would be able to weather any storm which might emerge due to any reason.
Glenmark Pharma Q2 Results: Co posts loss on exceptional legal costs
The company posted a consolidated net loss, from continuing operations, of 2.01 billion rupees ($24.14 million) for the three months ended Sept. 30, from a profit of 1.54 billion rupees a year ago
Zydus Lifesciences Q2 Results: Firm reports 53% YoY jump in net profit at Rs 801 crore
Revenue from operations rose 9.1% YoY to Rs 4369 crore in Q2FY24 compared to Rs 4006 crore in Q2FY23. On QoQ revenue declined 15%. The earnings before interest, tax, depreciation and ammortisation (EBITDA) increased 40.6% YoY to Rs 1146 crore. On QoQ, EBITDA dropped 23.9%.
Zydus Q2 Results: Profit jumps on strong domestic, US demand
India's generic drug makers, which draw a significant share of revenue from the crucial U.S. market, are recovering from the effects of eroding prices in the largest drug market in the world.
Fundamental Radar: Why Zydus Lifesciences is poised for strong earnings growth
Headquartered in Ahmedabad, Zydus Lifesciences is present across the pharmaceutical value chain of research, development, manufacturing, marketing, and sale of finished dosage human formulations, active pharmaceutical ingredients (APIs), animal healthcare products, and consumer wellness products.
Zydus Lifesciences Q1 Results: Net profit doubles to Rs 1,087 crore, revenue jumps 30%
US business grew by 57% YoY at Rs 2454 crores. India branded formulations grew by almost 12%, excluding impact of NLEM related price cut affecting some key products
Zydus Lifesciences Q1 Results: Profit more than doubles on US sales growth
Its U.S formulations business saw a revenue growth of 57.4% to 24.54 billion rupees, while India formulations grew by 9.1% to 12.27 billion rupees. India and U.S. sales make up 38% and 48% of Zydus' total revenue, respectively.
Nifty Pharma index hits a new high as investors lap up defensives
The Nifty Pharma Index jumped 1.56% on Monday to close at 15,479.25 as against the 0.4% advance in the benchmark Nifty. While the pharma index has beaten the Nifty so far in 2023, its outperformance has only widened since July 20-- when the Nifty came close to the milestone of 20,000--after which the index has struggled to maintain its bullish moves. The Nifty has fallen close to 2% since then, while the Nifty Pharma index gained 8.3% in this period.
Q1 results this week: LIC, Adani Ports, IRCTC, Hero MotoCorp, Nykaa and others
Adani Ports, Coal India, Siemens, Hindalco, Linde India, Lloyds Metals, Phoenix Mills, Oil India, Prestige Estates, Aarti Industries, Happiest Minds, Brigade Enterprises, Suven Pharma, Eureka Forbes and others will announce their June quarter results
Q1 results this week: Adani Enterprises, SBI, Maruti, Titan, Airtel, M&M & others
Major firms such as Maruti Suzuki, Titan, Bharti Airtel, and M&M among others will release their June quarter results this week. The report cards of other companies such as GAIL, Power Grid, Sun Pharma, and Adani Enterprises are also expected to be out. This week, Maruti Suzuki, Adani Enterprises, Adani Transmission, Titan, IndiGo, Bharti Airtel, Sun Pharma, SBI, M&M, Varun Beverages, and Bank of Baroda are scheduled to announce their quarterly performance.
HCL Tech Q1 Results: Profit rises 8% YoY to Rs 3,534 crore, misses estimates
HCLTech’s attrition for the quarter stood at 16.3% compared to 19.5% reported last quarter. The 12-month trailing attrition rate is at 16.3%, compared to 19.5% a quarter ago. Its headcount in the first quarter stood at 223,438 with a drop of 2,506 over the previous quarter, said Ramachandran Sundararajan, chief people officer. The company, however, added 1,597 freshers during the quarter.
Q1 earnings: 26 companies that may report over 100% jump in profit
Domestic brokerage Motilal expects Nifty earnings to grow 25% YoY in Q1. Oil and gas sector may report a 3x surge in profit YoY underpinned by the improvement in marketing margins of OMCs. Auto sector’s earnings may surge 11x YoY during the quarter on a low base.
Q1 results this week: TCS, HCL Tech, Wipro, Avenue Supermarts, Angel One and others
The June quarter earnings are seen to be weaker than expected amid uncertain and global environment and a slowdown in discretionary spending by clients
Zydus Lifesciences Q4 Results: Consolidated net profit dips 25% to Rs 297 crore
Zydus Lifesciences Ltd reported a 25.36% decline in consolidated net profit at Rs 296.6 crore in the fourth quarter ended March 31, 2023 impacted by impairment of goodwill of a wholly-owned subsidiary. The company, which had posted a consolidated net profit of Rs 397.4 crore in the same quarter of the previous fiscal, said its board has recommended a final dividend of Rs 6 per equity share of Re 1 each, subject to approval of shareholders at the
Sensex, Nifty trade on tepid note as poor quarterly earnings dent sentiment
In the Sensex pack, Infosys was the top laggard, falling over 1%. Asian Paints, Sun Pharma, HUL, HCL Tech and Nestle also opened lower. On the flip side, Tata Steel, M&M, L&T, HDFC, HDFC Bank and Power Grid opened with gains.
Zydus Lifesciences Q1 Results: Net Profit drops 12% YOY to Rs 518 crore
The earnings before interest, tax, depreciation and ammortisation (EBITDA) was Rs 833 crore, a decline of 14.3% YoY. On QoQ, EBITDA rose 16.1%.The EBITDA margins for the quarter dropped 190 basis points to 20.5% in Q1FY23 compared to 24.3% in Q1FY22. On QoQIndia sales saw a drop of 6.5% YoY to Rs 1817 crore in Q1FY23. The formulation business dropped .
Load More
